GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors -- Barrons.com
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating
Genedx Holdings Insider Sold Shares Worth $394,733, According to a Recent SEC Filing
Small-cap Stocks Have Climbed Recently. Here Are the Ones Most Poised for Further Upside
GeneDx Holdings Corp.'s (NASDAQ:WGS) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 12% Over the Past Week
GeneDx Holdings Initiated at Equal-Weight by Wells Fargo
Wells Fargo Initiates Coverage On GeneDx Hldgs With Equal-Weight Rating, Announces Price Target of $34
Is GeneDx Holdings (NASDAQ:WGS) A Risky Investment?
GeneDx Holdings(WGS.US) 10% Shareholder Sells US$4.76 Million in Common Stock
$GeneDx Holdings(WGS.US)$ 10% Shareholder OPKO HEALTH, INC. sold 139.82K shares of common stock on Aug 15, 16, 19, 2024 at an average price of $34.0204 for a total value of $4.76 million.Source:
Craig-Hallum Issues a Buy Rating on GeneDx Holdings (WGS)
GeneDx to Participate in Fall Investor Conferences
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
How Much Upside Is Left in GENEDX HOLDINGS (WGS)? Wall Street Analysts Think 40.34%
Appian, Bitfarms See Activist Action
GeneDx Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GeneDx Holdings Is Maintained at Buy by BTIG
GeneDx Holdings Price Target Raised to $45.00/Share From $35.00 by BTIG
Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $32
GeneDx Hldgs Analyst Ratings